KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Work In Process (2016 - 2017)

Biocryst Pharmaceuticals filings provide 3 years of Work In Process readings, the most recent being $1.3 million for Q2 2017.

  • On a quarterly basis, Work In Process fell 33.04% to $1.3 million in Q2 2017 year-over-year; TTM through Jun 2017 was $1.3 million, a 33.04% decrease, with the full-year FY2016 number at $500000.0, down 68.98% from a year prior.
  • Work In Process hit $1.3 million in Q2 2017 for Biocryst Pharmaceuticals, up from $655000.0 in the prior quarter.
  • In the past five years, Work In Process ranged from a high of $2.2 million in Q3 2016 to a low of $500000.0 in Q4 2016.
  • Median Work In Process over the past 3 years was $1.6 million (2015), compared with a mean of $1.5 million.
  • Biggest five-year swings in Work In Process: crashed 68.98% in 2016 and later tumbled 33.04% in 2017.
  • Biocryst Pharmaceuticals' Work In Process stood at $1.6 million in 2015, then crashed by 68.98% to $500000.0 in 2016, then soared by 161.0% to $1.3 million in 2017.
  • The last three reported values for Work In Process were $1.3 million (Q2 2017), $655000.0 (Q1 2017), and $500000.0 (Q4 2016) per Business Quant data.